Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of RXRX is 7.4 and suggests 79% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell